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Objectives: The pivotal trial of the Talent enhanced Low Profile System (eLPS; Medtronic Vascular, Santa Rosa, Calif)
stent graft evaluated short and long-term safety and efficacy of endovascular aneurysm repair (EVAR). These data and a
confirmatory group assessing the performance of the CoilTrac delivery system supported the United States premarket
approval application for the device.
Methods: The pivotal trial was a prospective, nonrandomized study conducted at 13 sites from February 2002 to April 2003.
The study group (n166) underwentEVARusing theTalent eLPS stent graft. The control group (n243) underwent open
surgical AAA repair. Data for this group were obtained from the Society for Vascular Surgery Endovascular AAA Surgical
Controls project. Outcomeswere compared at 30 days and 12months. Additional 5-year follow-upwas obtained for the eLPS
group. A single-center cohort of 137 patients was the confirmatory group for the assessment of the clinical performance of the
CoilTrac delivery system, with analysis of outcomes <30 days from the procedure.
Results: AAA anatomy with neck length as short as 3 mm and maximum neck diameter of 32 mm were included in the eLPS
group. EVAR was superior to open repair for periprocedural outcomes, including mean procedure duration (167.3 vs 196.4
minutes, P< .001), blood transfusion (18.2% vs 56.8%, P< .001), median intensive care unit stay (19.3 vs 74.3 hours, P<
.001), andmean hospital stay (3.6 vs 8.2 days, P< .001). Freedom frommajor adverse events was 89.2% for EVAR at 30 days
vs 44.0% (P < .001) and 81.3% vs 42.4% at 1 year (P < .001). Freedom from all-cause mortality and aneurysm-related
mortality (ARM)was 93.7% and 98.2% for EVAR vs 92.4% and 96.7% for the controls. Through 5 years for the EVARgroup,
rates of freedom from all-cause mortality, ARM, aneurysm rupture, and conversion to surgery were 69.8%, 96.5%, 98.2%, and
99.1%, respectively, with one conversion to surgery, 25 secondary reinterventions, and five site-reported instances of stent graft
migration. The technical success rate for the CoilTrac confirmatory group was 100%, with no aneurysm rupture or conversion
to open repair at 30 days. The 30-day all-cause mortality rate was 1.5% (2 of 137).
Conclusions: In a population with challenging anatomic characteristics, EVAR with the Talent eLPS and use of the
CoilTrac delivery system compared favorably with open repair through 1 year. Sustained protection from ARM, with
minimal reinterventions, was attained through 5 years. ( J Vasc Surg 2010;51:537-44.)From theDepartment of Surgery, Division of Vascular Surgery,Mount Sinai
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repair (EVAR) first became available in the early 1990s,1,2
many trials comparing the results of EVAR with conven-
tional open repair have confirmed the perioperative benefits
of EVAR.3-7 Diverse stent graft devices have evolved with
the intent of improving outcomes in patients with AAA
who have challenging anatomic characteristics. The Talent
abdominal stent graft (Medtronic Vascular, Santa Rosa,
Calif) was designed with larger diameters, extending its
indication to aneurysms with aortic necks from 18 to 32
mm in diameter. In addition, a proximal uncovered portion
allows for transrenal fixation, which may assist with the
treatment of aneurysms with short aortic necks.8,9
The Talent enhanced Low Profile System (eLPS;
Medtronic Vascular, Santa Rosa, Calif), with the CoilTrac
delivery system, received approval for use in EVAR from
the United States Food and Drug Administration (FDA) in
April 2008 based on data derived from the pivotal trial and
the CoilTrac confirmatory study. The pivotal trial evaluated
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historical open repair control group. Patients enrolled in
this study underwent EVAR using a prior iteration of the
delivery system (FlexTip). To support commercialization of
the Talent abdominal stent graft using the CoilTrac delivery
system, the data on the acute safety and effectiveness of the
delivery system was obtained from a sponsor-investigator in-
vestigational device exemption (IDE) study, defined as the
CoilTrac confirmatory group. The results obtained from
this study provided supportive clinical performance data for
the delivery system.
This report describes the data and analysis obtained from
theTalent eLPSpivotal trial out to 5 years of follow-up, aswell
as the results on the acute safety and effectiveness performance
of the CoilTrac delivery system.
METHODS
Study design. This was a prospective, nonrandom-
ized, multicenter, clinical trial using data collected from
patients who underwent EVAR using the Talent eLPS
stent graft. Between February 25, 2002, and April 14,
2003, 166 patients were enrolled from 13 investigational
sites throughout the United States (see Appendix, online
only), with 2 to 28 patients enrolled from each investiga-
tional site. Patients were eligible for entry into the eLPS
study if they were considered to have a low to moderate risk
for elective open repair of a nonruptured AAA or aortoiliac
aneurysm according to Society for Vascular Surgery (SVS)/
International Society for Cardiovascular Surgery (ISCVS)
scores of 0, 1, or 2.10,11 Approval was obtained from each
Institutional Review Board, and all patients provided in-
formed consent.
The eLPS group was compared with a historical open
repair control group of 243 patients who underwent open
AAA repair between November 1995 and March 2003.
This group was derived from the SVS Endovascular AAA
Surgical Controls Project, a comprehensive data set that
combines the control groups from multiple IDE studies
that have already been used individually to support ap-
proval of other endovascular devices. All analysis of the
control data was conducted by the New England Research
Institute, an independent reviewer, and served as the basis
for the comparative analysis with the eLPS group through
12 months of follow-up. The eLPS group was evaluated
additionally through 5 years.
End point definitions. The primary safety end point
was freedom from major adverse events (MAEs) 30 days
after EVAR or open repair. MAE included all-cause mor-
tality, myocardial infarction, renal failure, respiratory fail-
ure, paraplegia, stroke, bowel ischemia, and procedural
blood loss 1000 mL. All MAEs, with the exception of
procedural blood loss, were adjudicated by an independent
Clinical Events Committee (CEC). Additional safety end
points were freedom fromMAEs12months and freedom
from all-cause mortality 30 days of the procedure and at
12 months.
The primary effectiveness end point for the eLPS group
was defined as successful aneurysm treatment through 12months and required fulfillment of three criteria: technical
success, defined as successful delivery and deployment of
the stent graft; absence of AAA expansion, defined as
absence of 5 mm increase in transverse aortic diameter;
and absence of intervention for endoleak type I/III. Addi-
tional end points were freedom from endoleak; freedom
from stent graft migration, defined as evidence of proximal
or distal movement of the stent graft 10 mm relative to
the position on the first postoperative radiographic imag-
ing; stent graft patency; and freedom from secondary en-
dovascular procedures, defined as endovascular procedures
that involved the targeted vessel segment, manipulation of
the implanted graft, implantation of additional stent graft
devices or repeat intervention for endoleak.
Results from an independent core laboratory Jobst
Vascular Center (Toledo, Ohio) were used to evaluate end
points through 1 year. The1-year evaluations were made
using data reported from the sites. A description of the
device, patient selection, AAA morphology, endovascular
procedure, and follow-up criteria are discussed in the Sup-
plement (online only).
CoilTrac confirmatory group. Subsequent to en-
rollment in the pivotal trial, the delivery system was
updated to the CoilTrac delivery system. To evaluate the
clinical performance of the CoilTrac delivery system, a
confirmatory group of 137 patients was created from a
sponsor-investigator IDE study; enrollment took place
from April 2003 to November 2006. As inclusion criteria,
all individuals were high-risk patients who were not candi-
dates for open surgical repair as determined by preoperative
cardiac and pulmonary evaluations. Successful delivery and
deployment was defined as a successful implant procedure
that was not aborted and did not involve delivery system
malfunction.
The safety and effectiveness end points were assessed
through 30 days after the procedure. Reporting of this
acute clinical experience was based on clinically relevant
adverse events, intraoperative technical variables, and peri-
operative safety and efficacy outcome measures. To ensure
accurate reporting of the clinical data, all MAEs were
adjudicated by an independent CEC.
Statistical analysis. Comparability in demographic
and baseline characteristics was assessed between the Talent
eLPS and the SVS open repair groups. The Fisher exact test
was used for categoric data, and theWilcoxon rank sum test
was used for continuous or ordinal data. Differences in the
primary safety end point were analyzed by using a two-
sided 95% confidence interval (CI) and calculated by the
exact method. A propensity score analysis was also applied
to adjust the differences between the two study groups.
Kaplan-Meier analyses along with 95% CIs were provided
for comparison for survival and the primary safety end
points. Event rates were estimated for effectiveness end
points. Clinical utility measures were compared using the t
test or the Wilcoxon rank sum test, as appropriate. Differ-
ences were considered significant at P  .05. All data were
analyzed using SAS software (SAS Institute, Cary, NC).
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Talent eLPS preprocedural characteristics. The
eLPS group included older patients and higher percentage
of men than the control group. The mean age was 74.1 
7.5 years (range, 51-89 years) in the eLPS group vs 70.1
7.5 years (range, 46-86 years, P  .001) in the controls.
Men comprised 91.6% of the eLPS group vs 81.5% in the
control group (P  .004).
The data set provided information for a comparable
analysis of 11 baseline medical conditions. The eLPS group
had a higher rate of comorbid conditions at enrollment,
with a statistically significant difference in four of the base-
line medical conditions; these were hypertension, arrhyth-
mia, congestive heart failure, and peripheral vascular disease
(Table I).
The mean maximum aneurysm diameter was 57.1 
8.49mm (range, 43-87mm) for eLPS vs 56.9 11.59mm
(range 31 to 100 mm) for control (P  .826). The maxi-
mum aneurysm diameter was between 40 and 79 mm for
97.0% of the EVAR patients and 92.5% of the open repair
patients. In five of the open repair patients (2.3%) the
maximum aneurysm diameter was 40 mm and in 11
(5.2%) the maximum aneurysm diameter was 80 mm.
Aneurysm features in the eLPS group included 34% with
proximal necks 15 mm in length and 34% with proximal
necks 28 mm in diameter (Table II).
Talent eLPS procedural data. The eLPS stent graft
was successfully delivered and deployed in 162 patients
(97.6%). All 162 received a main bifurcated device and a
contralateral limb, and 94 (58.0%) received a device exten-
Table I. Patient characteristics
Variable
Stent graft, % Open repair, %
Pa(n  166) (n  243)
Age, mean  SD, y 74.1  7.49 70.1  7.49 .001
Male 91.6 81.5 .004
White ethnicity 92.8 94.9 .501
Angina 16.9 17.4 .999
Arrhythmia 44.0 11.5 .001
Cardiac revascularizationb 38.6 46.1 .154
Congestive heart failure 28.3 4.9 .001
Coronary artery disease 56.0 61.3 .306
Hypertension 83.7 66.7 .001
Myocardial infarction 38.6 34.2 .401
Peripheral vascular disease 46.4 15.6 .001
Diabetes 15.7 11.9 .303
COPD 39.2 30.0 .070
Smoking 84.9 85.6 .887
SVS score
0 (none/low) 6.0 NA
1 (mild) 47.6 NA
2 (moderate) 41.0 NA
3 (high/severe) 5.4 NA
COPD, Chronic obstructive pulmonary disease; NA, not available; SVS,
Society for Vascular Surgery.
aStatistical significance at P  .05.
bIncludes coronary artery bypass grafting or percutaneous transluminal
coronary angioplasty.sion of varying type to complete exclusion of the aneurysm,including 18 aortic extensions and 119 iliac extensions The
stent graft diameters were 22 to 36 mm, and 41.9% of
patients received a stent graft with a diameter 32 mm.
Three of the four technical failures were associated with
access issues due to diseased or calcified vessels. In a fourth
patient, the attempted EVAR resulted in a lacerated left
common femoral artery. The event was not considered
serious by the investigator, and the laceration was repaired
with a graft. No device malfunctions occurred. Acute pro-
cedural parameters demonstrated a consistent benefit for
the Talent eLPS compared with the control group, with a
shorter mean procedure duration and a reduction in blood
loss, transfusion requirements, and time in the intensive
care unit (Table III).
Talent eLPS safety analyses. The eLPS group exhib-
ited significantly improved 30-day freedom from MAEs of
89.2% compared with 44.0% for the control group (P 
.001), which persisted through 1 year (80.4% vs 41.7%, P
.001; Table IV). The rates of freedom from all-cause mor-
tality between the groups were not significantly different at
30 days (98.2% for eLPS and 97.1% for controls) and 12
months (93.7% for eLPS vs 92.4% for controls). There was
also no significant difference in freedom from ARM at 12
months (98.2% for eLPS vs 96.7% for controls). Three
deaths occurred 30 days after the procedure. Seven
deaths occurred during the first year, and only one was
related to the endovascular procedure. No aneurysm rup-
ture or conversions to open repair occurred during the first
12 months.
Talent eLPS effectiveness analyses. The primary ef-
fectiveness composite end point of successful aneurysm
treatment at 12months was achieved in 110 of 112 patients
(90.2%). Loss of procedural efficacy was attributed to four
technical failures, three cases of aneurysm growth 5 mm,
and five type I/III endoleaks that required reintervention
during the first year. Additional 12-month efficacy out-
comes included 95% freedom from AAA expansion, 93.2%
freedom from endoleak type I/III, 99.2% freedom from
stent graft migration, 89.5% freedom from secondary en-
dovascular procedures, and there was no loss of stent graft
patency.
Talent eLPS safety and efficacy outcomes through 5
years. Among patients who received the Talent eLPS stent
graft and were available for follow-up at 5 years, 36 patients
Table II. Baseline abdominal aortic aneurysm
morphology in the stent graft group as reported by the
core laboratory
Variable Mean SD Range
Proximal neck length, mm 22.9 12.48 3-75
Proximal neck diameter, mm 25.3 3.58 16-32
Maximum aneurysm diameter, mm 55.0 9.26 38-88
Right CIA diameter, mm 9.2 1.53 6-14
Left CIA diameter, mm 9.3 1.55 6-15
CIA, Common iliac artery; SD, standard deviation.died, the freedom from all-cause mortality was 69.8%, and
; ICU
c data
adver
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tion was obtained through telephone calls and review of the
Social Security Death Index at the end of the trial.
Two aneurysms ruptured, with one instance related to
AAA expansion; freedom from aneurysm rupture was
98.2%. One conversion to open repair was required in a
patient with type I and persistent type II endoleaks; free-
dom from conversion to open repair was 99.1%. Through-
out the trial, 25 secondary endovascular procedures were
performed; the rates were 1.2% (2 of 166)30 days, 10.2%
(16 of 157) from 31 to 365 days, 2.2% (3 of 138) for year
2 of follow-up, 1.7% (2 of 117) for year 3, 1.1% (1 of 95)
for year 4, and 1.4% (1 of 70) for year 5. Secondary
procedures were performed to correct 10 type II endoleaks
and 7 type I endoleaks (2 of which also were type III
endoleaks), stent kinking/twisting in 1, stenosis/throm-
bosis or occlusion in 4, and to maintain renal artery patency
in 3 patients. In some patients, multiple issues were cor-
rected in one procedure, and if a patient had multiple
secondary procedures within the same follow-up period, it
Table III. Acute procedural data
Variablea eLPS (EVAR
Procedure duration, min 167.3  53.1
Contrast use, mL 152.7  81.5
General anesthesia required, % 40.4
Estimated blood loss, mL 335.0  282
Blood transfusion required, % 18.2
ICU length of stay, h 19.3  73.8
Hospital length of stay, d 3.6  6.3
eLPS, Enhanced Low Profile System; EVAR, endovascular aneurysm repair
aContinuous data are presented as the mean  standard deviation, categori
Table IV. Major adverse events with Talent enhanced Lo
MAEs at 30 days eLPS  166% (n)
Overall 10.8 (18)
All cause death 1.8 (3)
Myocardial infarction 1.8 (3)
Renal failure 1.8 (3)
Respiratory failure 3 (5)
Paraplegia 0 (0)
Stroke 1.2 (2)
Bowel ischemia 0.6 (1)
Procedural blood loss 1000 mL 5.4 (9)
MAE at 12 months eLPS  153% (n)
Overall 19.6 (30)
All cause death 6.5 (10)
Myocardial infarction 3.9 (6)
Renal failure 3.3 (5)
Respiratory failure 3.9 (6)
Paraplegia 0 (0)
Stroke 2.6 (4)
Bowel ischemia 0.7 (1)
eLPS, Enhanced Low Profile System; CI, confidence interval; MAEs, majorwas only counted as one instance of reintervention.From the 71 evaluable subjects at the beginning of the
5-year follow-up interval, site-reported data were available
from 43 patients and from 14 patients for core laboratory
data. The rate of endoleak of any type according to core
laboratory data was 19.2% (29 of 151) in the first month
and 10.6% (12 of 113) during the interval from 30 days to
the 1-year follow-up. Through 5 years, site-reported en-
doleaks included nine type I, four type III, and 61 type II
(Table V).
Through the 5 years, there were five instances of stent
graft migration (reported as first instances only, with af-
fected patients censored from subsequent follow-up assess-
ments). Because the original study protocol included no
specific definition for migration in terms of minimum prox-
imal or distal movement, the movement in these five in-
stances might have been less than the value of10mm that
was subsequently used by the independent core laboratory
to report 1-year migrations in this report. Nomigration was
reported as serious, and there were no reported secondary
procedures to treat migration. The incidence rates for stent
Control (OR) P
196.4  82.99 .001
N/A N/A
98.7 .001
1347.5  1346.9 .001
56.8 .001
74.3  178.4 .001
8.2  7.9 .001
, intensive care unit; N/A, not applicable; OR, open repair.
are presented as percentage.
ofile System stent graft vs open repair
Control  243% (n) Difference, % (95% CI)
56 (136) 45.2 (52.6 to 36.9)
2.9 (7) 1.1 (4.4 to 2.8)
5.3 (13) 3.5 (7.6 to 0.4)
2.9 (7) 1.1 (4.4 to 2.8)
5.8 (14) 2.8 (7.0 to 1.7)
0.4 (1) 0.4 (2.3 to 2.0)
1.2 (3) 0 (2.6 to 3.3)
0 (0) 0.6 (1.0 to 3.6)
51 (124) 45.6 (52.9 to 38.1)
Control  240% (n) Difference, % (95% CI)
58.3 (140) 38.7 (47.2 to 29.4)
7.5 (18) 1.0 (6.1 to 5.0)
7.9 (19) 4.0 (8.9 to 1.4)
2.9 (7) 0.4 (3.2 to 5.0)
6.3 (15) 2.4 (6.8 to 3.0)
0.4 (1) 0.4 (2.4 to 2.2)
1.7 (4) 0.9 (2.1 to 5.0)
0 (0) 0.7 (0.9 to 3.9)
se events.)
.3w Prgraft migration per interval of follow-up were 0.9% (1 of
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year, 1.2% (1 of 83) during the third year, 1.9% (1 of 54)
during the fourth year, and 2.3% (1 of 43) during the fifth
year.
By core laboratory data, aneurysms were stable or de-
creasing in 97.5% at 1 year and 92.9% at 5 years, with 64.3%
reported as stable at 1 year, and 64.3% decreased in size at
the 5-year follow-up. The rates of site-reported AAA sac
regression were 32.2% at 1 year, 36.0% at 2 years, 41.9.0%
at 3 years, 39.7% at 4 years, and 51.2% at 5 years. Aneurysm
expansion was reported for the 5 years in 14 patients; of
these, 5 underwent a secondary procedure, 1 was converted
to open repair, and 1 had an aneurysm rupture; the remain-
ing 7 patients had no directly attributable outcomes during
their time in the trial.
CoilTrac confirmatory group. The patients in the
Fig 1. A, Kaplan-Meier analysis of freedom from all-cause mor-
tality for endovascular aneurysm repair (EVAR) using the Talent
enhanced Low Profile System (eLPS) stent graft. B, Kaplan-Meier
analysis of freedom from aneurysm-related mortality for EVAR
using the Talent eLPS stent graft. The range bars designate the
95% confidence interval.CoilTrac group were a mean age of 75.4  8.0 years and118 (86.1%) were men. The rates of their comorbidities,
grouped by body system, were 97.1% cardiovascular, 89.1%
pulmonary, 19.0% renal, and 10.9% from other abnormal
body systems. The average baseline maximum aneurysm
diameter was 61.3  10.5 mm.
Successful delivery and deployment was achieved in 100%
of patients undergoing EVAR using the CoilTrac delivery
system with the Talent abdominal stent graft. Two deaths
occurred 30 days of the procedure. One patient died of
congestive heart failure at 18 days, and the other died of
aspiration pneumonia at 24 days.
The rate for clinically relevant adverse events was
15.3% (Table VI). Clinical data were also evaluated for
the presence of MAEs for a comparable analysis of the
safety end points to the eLPS group; the rate of MAEs
for the CoilTrac group was 4.4% (Table VII). No aneurysm
rupture, conversion to open repair, branch vessel occlusion,
or device migration occurred 30 days of follow-up.
DISCUSSION
The Talent eLPS differs from the earlier version Talent
LPS in two respects: it incorporates a new nitinol metal
surface finish, and the longitudinal connecting bar of the
ipsilateral iliac limb was changed from a lateral to a medial
position. These modifications were designed to improve
ease of deployment and durability of treatment (Fig 2).9
The eLPS has been commercially distributed since 2002
and the CoilTrac delivery system since 1999. Both have
been available in 80 countries, with 25,000 Talent
abdominal stent grafts using the CoilTrac delivery system
distributed worldwide.
In this nonrandomized multicenter study, EVAR using
the Talent eLPS stent graft was associated with better
periprocedural results and fewer major short-term andmid-
term (1-year) complications than open repair, as repre-
sented by the data set from the SVS Lifeline Registry. The
benefits of EVAR in terms of periprocedural results and
midterm freedom from MAE and ARM occurred in pa-
tients both older and with more comorbidities than in the
SVS open repair counterparts. Extended follow-up of the
EVAR cohort though 5 years demonstrated favorable rates
of freedom from all-cause mortality, ARM, aneurysm rup-
ture, and conversion to surgery, with only one conversion
to open repair, five site-reported instances of stent graft
migration (none of which required reintervention), and 25
secondary interventions, of which 72% were performed1
year.
EVAR is being used increasingly for the treatment of
AAA. Clinical trials demonstrate that EVAR is character-
ized by significantly less short-term morbidity and mortal-
ity compared with conventional surgical treatment.7,12
Long-term data on the durability and cost-effectiveness of
the EVAR procedure remain limited, however.13,14
Previous reports evaluating the safety of the Talent
stent graft demonstrate satisfactory results with low com-
plication rates.15-17 The initial reports of the pivotal trial
indicated a deployment success rate of 98.7% and device or
procedure related complications of only 3.7%.9,18 Survival
is vari
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years have been reported.16,19 In a European multicenter
study, the perioperative mortality was 1.8%, with only one
ARM (0.3%) during a mean follow-up of 25 months, with
cumulative reintervention rates of 6%, 8%, 13%, and 16% at
1, 2, 3, and 4 years, respectively, and a graft migration rate
Table V. Site-reported endoleaks through 5 years of exten
Endoleak
1 mon (1-90 d) 1 y (305-354 d) 2 y (548
No. (%) No. (%) No.
(n  156)a (n  121) (n 
Any type 38 (24.4) 15 (12.4) 9 (
Type I 3 (1.9) 0 (0.0) 2 (
Type II 26 (16.7) 12 (9.9) 6 (
Type III 3 (1.9) 0 (0.0) 0 (
Type IV 3 (1.9) 0 (0.0) 0 (
Indeterminate 13 (8.3) 4 (3.3) 4 (
aPercentages calculated based on the number of individuals evaluable for th
Table VI. Clinically relevant delivery-system adverse
events in the CoilTrac confirmatory groupa
Event
No. (%)
(N  137)
Perioperative death 2 (1.5)
AAA rupture 0 (0)
Conversion to open repair 0 (0)
Branch vessel occlusion: RA/SMA 0 (0)
Stent graft occlusion 2 (1.5)
Stent graft migration 0 (0)
Device-specific endoleaks
Type I 7 (5.1)
Type III 0 (0)
Unknown type 5 (3.7)
Access site wound infection 3 (2.2)
Access site wound hematoma 5 (3.6)
Total 21 (15.3)
AAA, Abdominal aortic aneurysm; RA, renal artery; SMA, superior mesen-
teric artery.
aDefined as the presence of any of the listed events 30 days after the
procedure.
Table VII. Major adverse events in the CoilTrac
confirmatory groupa
Category
No. (%)
(N  137)
All-cause mortality 2 (1.5)
Myocardial infarction 0 (0)
Renal failure 0 (0)
Respiratory failure 1 (0.7)
Paraplegia 0 (0)
Stroke 0 (0)
Bowel ischemia 0 (0)
Procedural blood loss 1000 mL 4 (2.9)
Total 6 (4.4)
aMajor adverse events related to the delivery system, defined as for the
enhanced Low Profile System group, by the presence of any of the listed
events, observed 30 days after the procedure.of 2.4% of patients/year.20Furthermore, the Talent abdominal stent graft demon-
strates adequate performance compared with other stent
grafts, particularly in patients who have challenging anat-
omy at the aortic fixation site.9,21,22 The satisfactory results
presented in this pivotal trial reinforce the data obtained
from previous single and multicenter reports evaluating the
Talent stent graft.
The efficacy of EVAR relies on complete exclusion of
the aneurysm sac while simultaneously preventing AAA
expansion. Treatment using EVAR has resulted in low rates
of aneurysm expansion of 8.7% after 6 months of follow-
up15 and demonstrable sac shrinkage of 52%  9.7% at 12
follow-up
d) 3 y (914-1278 d) 4 y (1279-1644 d) 5 y (1645 d)
No. (%) No. (%) No. (%)
(n  87) (n  56) (n  43)
11 (12.6) 7 (12.5) 5 (11.6)
1 (1.1) 2 (3.6) 1 (2.3)
8 (9.2) 5 (8.9) 4 (9.3)
0 (0.0) 1 (1.8) 0 (0.0)
0 (0.0) 0 (0.0) 0 (0.0)
3 (3.4) 2 (3.6) 1 (2.3)
able.
Fig 2. The Talent enhanced Low Profile System (eLPS) stent
graft differs from the previous Talent LPS stent graft in two
respects: (1) it incorporates a new nitinol-component metal surface
finish, and (2) it has medial, not lateral, placement of the longitu-
dinal connecting bar in the ipsilateral iliac limb.ded
-913
(%)
91)
9.9)
2.2)
6.6)
0.0)
0.0)
4.4)months.23 Freedom from endoleak has been reported to be
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months, and 90% at 12 months.18 The risk for any type of
endoleak has been reported to be 19%  7.1% at 12
months.23
This study demonstrated significantly improved free-
dom from MAE at 30 days and 12 months in the Talent
eLPS group compared with the control group, indicating
that patients undergoing open repair were more likely to
present a MAE1 year after the procedure compared with
those who underwent EVAR with the eLPS stent graft.
This substantially superior safety performance in the eLPS
group compared with the control group occurred even
though the eLPS patients had baseline comorbidities that
put them at a significantly greater risk of complications. In
addition, the population included in the eLPS group pre-
sented challenging anatomic characteristics: more than
one-third of the patients featured a neck diameter28 mm
or a neck length 15 mm, and despite this fact, the
outcomes were still comparable with the results from other
approved devices.24-27
Other safety outcome measures showed comparable
results between both groups. The primary efficacy end
point for patients treated using the Talent eLPS stent graft
demonstrated an excellent technical success, with no de-
vice-specific failures. Reduction or stability of aneurysm
diameter is critical to the long-term success of aneurysm
exclusion. The change in maximum aneurysm diameter was
analyzed, and these results demonstrate a high degree of
success based on these criteria, where 95% of the aneu-
rysms were stable or decreasing in size at 12 months.
Additional effectiveness outcomes were analyzed by the
type of endoleak and the freedom from secondary endovas-
cular procedures at 12months. Patients whowere free from
type I/III endoleak and did not undergo a secondary
endovascular procedure comprised 93.2% of the group.
Extended follow-up of the eLPS group continues to show
sustained high rates of safety and effectiveness outcomes,
with excellent rates of freedom from ARM, freedom from
conversion to open repair, and only two aneurysm ruptures.
The clinical data obtained from the patients evaluated
in the CoilTrac confirmatory study supported the clinical
performance of the delivery system, as demonstrated by the
technical success rate of 100% and the low 30-day compli-
cation rate, with only 4.4% of the MAEs in a population
consisting of medically high-risk patients. These data con-
tributed to provide evidence of the safe and effective per-
formance of the Talent abdominal stent graft with the
CoilTrac delivery system.
CONCLUSIONS
The results obtained from the pivotal clinical trial and
the CoilTrac confirmatory group support the safety and
efficacy of the Talent eLPS stent graft using the CoilTrac
delivery system for use in EVAR. This is demonstrated by
the high technical success rate as well as the improved acute
outcomes observed in the patients treated with the Talent
eLPS abdominal stent graft compared with the control
group. These results were achieved in a patient populationthat manifested a significant degree of challenging ana-
tomic parameters and extensive comorbid medical condi-
tions. The sustained safety and efficacy outcome rates ob-
served in the 5-year follow-up further support its reliability
to achieve continued successful aneurysm treatment.
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Trial centers. Investigators and institutions partici-
pating in the Talent eLPS Abdominal Stent-Graft Pivotal
Trial: Frank Criado, MD, Union Memorial Hospital, Bal-
timore,Md; Barry Katzen,MD, Baptist Cardiac &Vascular
Institute, Miami, Fla; Renan Uflacker, MD, Medical Uni-
versity of South Carolina, Charleston, SC; Mike Belkin,
MD, Brigham&WomensHospital, Boston,Mass;Michael
Hallisey, MD, Hartford Hospital/Connecticut Surgical
Group, Hartford, Conn; Paul Bove, MD, William Beau-
mont Hospital, Royal Oak, Mich; Ronald Fairman, MD,
University of Pennsylvania Medical Center, Philadelphia,
Pa; Timothy Roush, MD, The Sanger Clinic, Charlotte,
NC; Rodney White, MD, Harbor/UCLAMedical Center,
Torrance, Calif; Christopher Zarins, MD, StanfordUniver-
sity Medical Center, Stanford, Calif; Brian Rubin, MD,
Washington University School of Medicine, St. Louis, Mo;
Robert Allen, MD, Cleveland Clinic Foundation, Naples,
Fla; and Michael Khoury, MD, St. Joseph Mercy of Ma-
comb, St. Clair Shores, Mich.
The CoilTrac sponsor-investigator IDE study was con-
ducted by Michael L Marin, MD, Mount Sinai School of
Medicine, New York, NY.
SUPPLEMENT (online only)
Device description. The Talent eLPS is a self-expand-
ing modular device composed of a nitinol metal stent
attached to a polyester fabric vascular graft.9 The metal
stent frame is made of a small-diameter nitinol wire formed
into a series of ring-like serpentine stents and attached
along a medially placed longitudinal nitinol connecting bar
to provide column strength. The stent frame is sewn with
polyester suture to the lumen of a polyester graft. Platinum
iridium marker bands are sewn into the stent graft to aid in
the visualization and accurate placement of the device.
The main bifurcated body consists of a single ipsilateral
limb and a contralateral stub leg. A contralateral iliac limb is
designed for mating with the contralateral stub of the
bifurcated main body.
The device is available in standard catalog configura-
tions as well as in designs customized to specific patient
anatomy. The bifurcated main body portion is available in
diameters of 22 to 36 mm for the proximal aorta and 12 to
20 mm for the distal ipsilateral iliac extension. For the
contralateral limb, available distal iliac diameters range
from 8 to 24 mm.
The CoilTrac delivery system is a flexible catheter con-
structed of three concentric single lumen polymer shafts
(an outer graft cover, a pushrod, and a guidewire lumen). A
metallic coil stent stop is attached to the distal end of the
pushrod to maintain stent graft position during deploy-
ment. A compliant balloon is located on the distal end of
the delivery system to aid in stent graft modeling, if neces-
sary. At deployment, the balloon is inflated sequentially
along the length of the endograft to optimize apposition to
the vessel wall and between modular components.Patient selection. Patients included in the trial were
suitable candidates for elective surgical repair of nonrup-
tured AAA and aortoiliac aneurysm. Further inclusion cri-
teria were dilated aneurysms 4.0 cm in diameter, 1.5
times the diameter of the native aorta or symptomatic; a
proximal AAA neck 5 mm in length and between 14 and
32mm in diameter, with60° angulation as demonstrated
by radiologic imaging; a distance between the renal arteries
and the aortic bifurcation of 9 cm; a distal iliac neck
length of15 mm; and distal iliac neck diameters between
8 and 18 mm. At least 1 internal iliac artery had to be
patent. Patients also had to be available for 12 months of
postprocedural follow-up.
Patients were excluded from the pivotal trial if they
were deemed at high risk for elective surgical repair (SVS/
ISCVS score 3). Further exclusion criteria were a “domi-
nant” inferior mesenteric artery and an occluded or stenotic
celiac and superior mesenteric artery; a circumferential mu-
ral thrombus at the proximal neck; an aneurysm involving
both internal iliac arteries; no distal vascular bed (1-vessel
run-off was required); a known allergy to the fabric or metal
components of the stent graft device; an untreated bleeding
diathesis or a hypercoagulable state; a history of congenital
degenerative collagen disorders; a systemic infection; a
history of contraindications to contrast agents; and an
episode of myocardial infarction (MI), cerebral vascular
accident (CVA), or major surgery 3 months. Current
participation in another clinical trial was also a reason for
exclusion.
Surgical control patients. In 1998, the SVS estab-
lished a database for EVAR to evaluate long-term out-
comes.28,29 The database collected results from five multi-
center controlled clinical trials considered by the FDA for
approval of the An-Cure (Guidant, Indianapolis, Ind),
AneuRx (Medtronic, Santa Rosa, Calif), Excluder (W. L.
Gore & Associates, Flagstaff, Ariz), PowerLink (End-
ologix, Irvine, Calif), and Zenith (Cook, Bloomington,
Ind) endovascular stent grafts. Each of these IDE trials
compared the use of these stent grafts for EVAR with open
surgical repair. As required by the FDA, the accuracy of
data collection was confirmed and verified by independent
audit. The results of the individual trials and the overall SVS
database have been published.4,5,30-34 The database is ad-
ministered by the New England Research Institute (NERI)
on behalf of the SVS Outcomes Committee.
For the 30-day and 1-year comparison of the outcomes
of EVAR using the Talent eLPS stent graft vs the outcomes
of open repair based on SVS surgical controls, NERI iden-
tified complete data sets for three of the five manufacturers,
totaling 243 surgical control patients. The open surgical
repairs in these patients took place between November 22,
1995, and March 27, 2003. NERI examined the poolabil-
ity of the three separate patient populations, looking at
demographics and medical history, preoperative AAA di-
ameter, and procedural results. One of these three surgical
control populations contained more patients with a history
of arrhythmia than the other two surgical control popula-
tions (18.9% vs 3.0% and 7.6%, P  .003). History of
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analyses in this current study were performed.
Preoperative assessment of AAA morphology. All
patients underwent conventional angiography with a cali-
brated catheter and computed tomography (CT) with min-
imum 3-mm slices. Imaging studies were verified by an
independent core reference laboratory at Jobst Vascular
Center in Toledo, Ohio. The followingmeasurements were
made in each patient by each site’s investigators: proximal
neck diameter immediately below the distal-most renal
artery (D1); diameter of the distal nonaneurysmal aortic
neck (D2); diameter of the aneurysm at its widest (D3);
diameter of the terminal aorta just above the bifurcation (if
applicable) (D4); diameter of the iliac arteries; length of the
neck (L1), aneurysm (L2), and distal aortic neck (if appli-
cable) (L3); length from the distal-most renal artery to the
aortic bifurcation (L4); length from the aortic bifurcation
to each hypogastric artery origin; and the angle between the
proximal AAA neck and the main axle of the AAA.
Stent graft procedure. Endovascular implantation of
the Talent eLPS stent graft was performed after adminis-
tration of regional (spinal or epidural) or local anesthesia,
or general anesthesia. Access to the common femoral arter-
ies was by surgical cutdown. A 22F or 24F delivery sheath
was used to introduce the device into the aorta, followed by
deployment in the suprarenal segment. Delivery and de-
ployment of the contralateral limb of the device was with an
18F or 20F sheath. The implant procedure was performed
under fluoroscopic and angiographic guidance. Patients
received anticoagulants during the implant procedure (with
a recommended activated clotting time of 200 to 300
seconds). Antiplatelet therapy was at investigator discre-
tion. Composition of the interventional team varied across
sites, with only surgeons at some sites and with combina-
tions of surgeons, radiologists, and cardiologists at other
sites.
Follow-up evaluation. Before hospital discharge, pa-
tients who received a stent graft underwent a physicalexamination and clinical laboratory tests and two-view (an-
teroposterior and lateral) plain abdominal radiograph and
CT to evaluate device placement, graft patency, aneurysm
size, renal artery patency, and presence or absence of en-
doleak. CT recommendations included contrast and non-
contrast phases and a minimum of 3-mm sections. The
same studies were repeated at 1, 6, and 12 months, and
annually thereafter. All preoperative and postoperative
films were reviewed locally at each investigational site and
also by the independent core laboratory.
Safety end points. Freedom from MAEs was the pri-
mary safety end point. The elements that comprised MAEs
included:
1. myocardial infarction (MI), defined as the presence of
two of the following conditions, new clinical symptoms
suggesting MI, abnormal electrocardiogram findings
and elevated creatine kinase exceeding twice the normal
level;
2. renal failure, defined as dialysis requirement or elevated
creatinine greater than twice the baseline level;
3. respiratory failure, defined as the need for mechanical
ventilation 24 hours after the procedure or reintuba-
tion;
4. stroke, defined as development of a new neurologic
deficit persisting24 hours or worsening of neurologic
symptoms for 24 hours;
5. bowel ischemia, defined by either colonoscopic or post-
mortem demonstration of ischemic changes;
6. paraplegia;
7. procedural blood loss 1000 mL; and
6. all-cause mortality.
The safety end points analyzed for the eLPS group only
included freedom from ARM, aneurysm rupture and con-
version to surgery. Deaths for the eLPS group were re-
viewed and adjudicated by the CEC for relationship to the
device, procedure, or aneurysm.
